The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
about
The importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseNeuroscience in the era of functional genomics and systems biologyHistone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiencyEpigenetics and Triplet-Repeat Neurological DiseasesTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesThe many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapyTransgenic animal models for study of the pathogenesis of Huntington's disease and therapyMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.The interplay between microRNAs and histone deacetylases in neurological diseasesTranscriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasisProfiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitorsMolecular mechanisms of synaptic remodeling in alcoholismThe promise and perils of HDAC inhibitors in neurodegenerationEpigenetic mechanisms of neurodegeneration in Huntington's diseaseEvaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelDecreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulationOral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivoEffects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's DiseaseInduction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse ModelSelective toxicity by HDAC3 in neurons: regulation by Akt and GSK3betaNanopublications for exposing experimental data in the life-sciences: a Huntington's Disease case studyGenetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's diseaseProlonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse modelValproic acid attenuates intercellular adhesion molecule-1 and E-selectin through a chemokine ligand 5 dependent mechanism and subarachnoid hemorrhage induced vasospasm in a rat model.Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's diseaseHistone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.Development of histone deacetylase inhibitors as therapeutics for neurological diseasePharmacology of epigenetics in brain disordersThe histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease miceGenome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling.Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencingD-β-hydroxybutyrate is protective in mouse models of Huntington's disease.Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactionsHistone deacetylase complexes promote trinucleotide repeat expansionsScriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway : scriptaid protects against TBI via AKT.Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads databaseDownregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.
P2860
Q22306292-F6D3CA55-205D-4FDA-861B-BAADB12DB5F8Q22337243-CBAF264A-0F7F-4514-84AD-722D8E834866Q24619820-35A52D46-9B4F-4B4C-83D0-D43C2DBC6AA8Q26770705-7F068079-9491-47C2-BD90-170C36657D5AQ26771812-12A15D71-818F-4A81-B4AF-DF08DAB2D24FQ26823365-870790F3-52F2-4A25-A1FD-21DB2E63FEADQ26849677-8FAA0D5D-1592-47D7-91DC-4E9F6BF7CBF8Q27005950-24533234-3735-45D8-BEC7-0F709AF41D9FQ27024466-85996816-55A7-4342-A8EE-7605116924BFQ27026549-364ED202-E419-408E-AA1B-C03FE6C1169CQ28079587-FFFE908F-6E95-4B52-9693-B28E2EE3E5DEQ28080843-90B51255-595C-40E7-AE19-3118C715CE9DQ28087539-308093EE-5472-4D2D-9AB1-8A60CD163F92Q28297936-94B4A616-4DE0-4C86-8485-39007BAAC788Q28475537-351B42DB-4549-4E7B-9202-13F9D4296C96Q28479035-9B4CD727-CA7E-450E-B7A7-5481B46D59CDQ28483335-2CCFDC36-4120-489D-92DF-3D6D5738A4CCQ28486205-5374F98E-9EE8-4AFB-840A-CFDD7A002B66Q28534553-E254212D-6657-4818-975F-ED6B4C731CEBQ28546885-38786A0D-89D8-40D7-AF08-14C7DA3DDF79Q28565080-638B11D3-4EAF-40C2-A39D-704D2A5803B1Q28606409-31D42844-2784-491D-A6BB-62D3DB8ED083Q28732195-5721DCF4-23C9-4921-A98F-4E0A12FE1602Q28743986-5CE2F668-D997-474D-B89C-E2EC9F22DF05Q30413642-EAC715A6-1EEE-457B-A04C-CA26CA8A574EQ30426968-67305447-57B4-4BF8-9705-7AB4F31D4B16Q33457171-9EF69E84-ADFC-4CBA-A6E5-4FE612644065Q33613257-90E2C0AE-2FDC-45D3-8F32-48DAB7B0EFBCQ33670661-305237CA-7D63-4FC3-9E50-3F4775D038B8Q33673025-3532BD1D-D87B-497C-AE73-B268A871C29BQ33784471-171DB661-F77A-4977-98D0-BD8153712D55Q33920945-55C2B22B-B0BE-4D80-86CF-FFE53B63D084Q34017754-9634F8C1-2299-47A6-8331-22A6241E4858Q34019122-D71804C1-11C6-4274-85F7-797C8BB7EDC2Q34023773-2BD00DD0-0619-49BF-8440-EB65A4ED68C4Q34144718-07F0A891-F975-4B35-AF66-3CAE3BC3C102Q34169694-944DFEFD-8CF7-4675-92C9-508C35955DFDQ34310319-F6D09645-A9BC-449A-B29A-C233B9B7ECC9Q34319766-7005BDC3-6B9F-4F99-ADD1-08D7677B8928Q34431341-A188AB1A-A82D-4BA7-A159-F8E76717BE5C
P2860
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The HDAC inhibitor 4b ameliora ...... gton's disease transgenic mice
@nl
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@ast
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@en
type
label
The HDAC inhibitor 4b ameliora ...... gton's disease transgenic mice
@nl
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@ast
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@en
prefLabel
The HDAC inhibitor 4b ameliora ...... gton's disease transgenic mice
@nl
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@ast
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@en
P2093
P2860
P3181
P356
P1476
The HDAC inhibitor 4b ameliora ...... ton's disease transgenic mice.
@en
P2093
Daniel H Geschwind
David Herman
Elisabetta Soragni
Elizabeth A Thomas
Fuying Gao
Giovanni Coppola
Jenna F Borok
Joel M Gottesfeld
Kelsey M Fitzgerald
P2860
P304
15564-15569
P3181
P356
10.1073/PNAS.0804249105
P407
P577
2008-09-30T00:00:00Z